Clinical Takeaway
In this small pilot trial of 20 adults with diagnosed insomnia disorder, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo, suggesting that at least this cannabinoid combination and dosing regimen did not improve objective sleep duration. Patients and clinicians should be cautious about assuming that cannabinoid products reliably improve sleep architecture, as the evidence base remains limited and effects may differ from subjective impressions.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-resolution electrophysiological characterization of how a standardized THC/CBD combination affects sleep architecture in clinically diagnosed insomnia patients, filling a critical evidence gap that has driven uncontrolled patient use of cannabis for sleep. The use of 256-channel high-density EEG enables detection of sleep stage-specific and regional brain activity changes that conventional polysomnography cannot resolve, potentially identifying whether cannabinoid effects on subjective sleep improvement reflect genuine architectural improvements or represent altered sleep perception. These findings are essential for clinical decision-making regarding cannabinoid prescription in insomnia and for establishing safety parameters around next-day cognitive and alertness impairment.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study adds useful objective data to a clinically common scenario, though several limitations warrant cautious interpretation. The small sample size (n=20), single-dose design, and predominance of female participants limit generalizability, and the study does not clarify whether observed EEG changes translate to clinically meaningful improvements in insomnia severity or daytime functioning over time. The specific THC/CBD ratio tested (10 mg THC with 200 mg CBD) may not reflect typical patient dosing patterns or individual cannabinoid sensitivities, and importantly, we lack data on tolerance development, next-day cognitive effects, or comparative efficacy against standard sleep interventions. For clinicians considering cannabinoids in insomnia, this research suggests potential neurophysiological activity but falls short of establishing clear therapeutic advantage; patients remain best counseled that evidence-based sleep hygiene and cognitive behavioral therapy for insomnia remain first-line, while cannabinoids might be considered as adjunctive therapy only after discussion of the limited evidence